EUVIMEDEUVIMED entdecken
Crossref

Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer

Kazzem Gheybi, Jue Jiang, Shingai B A Mutambirwa, Pamela X Y Soh, Zsofia Kote-Jarai, Weerachai Jaratlerdsiri, Rosalind A Eeles, M S Riana Bornman, Vanessa M Hayes

Journal of the National Comprehensive Cancer Network · 2023

DOI: 10.6004/jnccn.2022.7097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023. Verfasst von Kazzem Gheybi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ancestry & Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Genetic Testing, Prostatic Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline testing for prostate cancer is on the increase, with clinical implications for risk assessment, treatment, and management. Regardless of family history, NCCN recommends germline testing for patients with metastatic, regional, very-high-risk localized, and high-risk localized prostate cancer. Although African ancestry is a significant risk factor for aggressive prostate cancer, due to a lack of available data no testing criteria have been established for ethnic minorities. Patients and Methods: Through deep sequencing, we interrogated the 20 most common germline testing panel genes in 113 Black South African males presenting with largely advanced prostate cancer. Bioinformatic tools were then used to identify the pathogenicity of the variants.

Results

After we identified 39 predicted deleterious variants (16 genes), further computational annotation classified 17 variants as potentially oncogenic (12 genes; 17.7% of patients). Rare pathogenic variants included CHEK2 Arg95Ter, BRCA2 Trp31Arg, ATM Arg3047Ter (2 patients), and TP53 Arg282Trp. Notable oncogenic variants of unknown pathogenicity included novel BRCA2 Leu3038Ile in a patient with early-onset disease, whereas patients with FANCA Arg504Cys and RAD51C Arg260Gln reported a family history of prostate cancer. Overall, rare pathogenic and early-onset or familial-associated oncogenic variants were identified in 6.9% (5/72) and 9.2% (8/87) of patients presenting with a Gleason score ≥8 or ≥4 + 3 prostate cancer, respectively.

Conclusions

In this first-of-its-kind study of southern African males, we provide support of African inclusion for advanced, early-onset, and familial prostate cancer genetic testing, indicating clinical value for 30% of current gene panels. Recognizing current panel limitations highlights an urgent need to establish testing guidelines for men of African ancestry. We provide a rationale for considering lowering the pathologic diagnostic inclusion criteria and call for further genome-wide interrogation to ensure the best possible African-relevant prostate cancer gene panel.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingProstatic NeoplasmsMaleHumansRisk FactorsGerm CellsGerm-Line MutationGenetic Predisposition to Disease

Stichwörter der Autor:innen

African ancestryGermline testingadvanced diseasepathogenic variantsprostate cancer

Autor:innen und Institutionen

  • Ancestry & Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Camperdown, NSW, Australia.
  • Department of Urology, Sefako Mekgatho Health Sciences University, Dr. George Mukhari Academic Hospital, Medunsa, South Africa.
  • Oncogenetics Team, The Institute of Cancer Research, Surrey, United Kingdom.
  • School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.

Zitieren

APA

Gheybi, K., Jiang, J., Mutambirwa, S. B. A., Soh, P. X. Y., Kote-Jarai, Z., Jaratlerdsiri, W., Eeles, R. A., Bornman, M. S. R., & Hayes, V. M. (2023). Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2022.7097

Vancouver

Gheybi K, Jiang J, Mutambirwa SBA, Soh PXY, Kote-Jarai Z, Jaratlerdsiri W, et al. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer. Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2022.7097

BibTeX
@article{Gheybi2023,
  author = {Gheybi, Kazzem and Jiang, Jue and Mutambirwa, Shingai B A and Soh, Pamela X Y and Kote-Jarai, Zsofia and Jaratlerdsiri, Weerachai and Eeles, Rosalind A and Bornman, M S Riana and Hayes, Vanessa M},
  title = {Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2023},
  doi = {10.6004/jnccn.2022.7097}
}
Kostenlos starten →